IFNB1 and COVID-19: Given the emerging evidence that lopinavir/ritonavir treatment may be ineffective against SARS-CoV-2, the ongoing trial had been amended to compare the therapeutic effectiveness of IFNβ with remdesivir, a viral polymerase inhibitor that has demonstrated limited therapeutic efficacy in COVID-19 cases.